Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
6.43
0.00 (0.00%)
May 12, 2025, 4:00 PM - Market closed
Anbio Biotechnology Revenue
In the year 2024, Anbio Biotechnology had annual revenue of $8.19M with 21.95% growth. Anbio Biotechnology had revenue of $2.34M in the half year ending December 31, 2024, a decrease of -59.05%.
Revenue (ttm)
$8.19M
Revenue Growth
+21.95%
P/S Ratio
33.22
Revenue / Employee
$303,154
Employees
27
Market Cap
282.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.19M | 1.47M | 21.95% |
| Dec 31, 2023 | 6.71M | -16.83M | -71.49% |
| Dec 31, 2022 | 23.54M | 19.12M | 431.67% |
| Dec 31, 2021 | 4.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNNNN News
- 2 months ago - U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings - Seeking Alpha
- 2 months ago - Anbio Biotechnology Announces Closing of Initial Public Offering - GlobeNewsWire
- 2 months ago - Anbio Biotechnology Announces Pricing of Initial Public Offering - GlobeNewsWire
- 4 months ago - U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings - Seeking Alpha
- 4 months ago - Anbio Biotechnology Pursues U.S. IPO For Its IVD Products Launch - Seeking Alpha
- 4 months ago - Anbio Biotechnology IPO Registration Document (F-1) - SEC